Sinovac Biotech Co., Ltd

This study tests a new vaccine designed to prevent hand, foot, and mouth disease (HFMD) and herpangina in children aged 6 months to 5 years. About 6,000 healthy children will receive either the vaccine or a placebo to see if it safely protects against four common virus types that…

This Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…

This Phase 3 trial tests a new meningococcal conjugate vaccine in 660 healthy children aged 2-6 years. The vaccine targets four strains (A, C, Y, W135) that cause meningitis. Participants receive one shot and provide blood samples to compare immune response with a licensed vaccin…

This study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …

This Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…

This early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for large…

This study tests whether three different batches of a rabies vaccine work the same way and are safe. It involves 912 healthy adults aged 18 to 45. The goal is to make sure every batch produces a strong immune response.